Home Featured Page 55

Featured

Latest

At the Federal Psychedelic Medicine Summit, the Mood Was Urgent, Practical, and Increasingly Coordinated

Bit Yaden on Preparing the Next Generation of Psychiatrists for a Psychedelic Future

“If I can’t change my views based on evidence, then why do science at all?” Nora Volkow on Psychedelics

Q4 2025: Oregon Psilocybin Services Update

Psilocybin for Chronic Suicidal Ideation: Scott T. Aaronson on Safety, an Efficacy Signal, and the Role of Expectations

Expanding Psychedelic Clinical Trials to LGBTQ+ Populations

An Inside Look at the FDA and Early Drug Development

In Conversation: Joanna Kempner, Author of “Psychedelic Outlaws: The Movement Revolutionizing...

Community, Group Process, and Co-Creation: How to Build a Successful Retreat

Pα+ Psychedelic Bulletin #164: Lykos Dominates News Cycle; EPIsoDE Trial Readout;...

Breaking: Lykos Therapeutics Moved to Patent MDMA In Late 2022, Filing...

Why Are Some Parents Choosing Psychedelics Over SSRIs for Teens?

Natural Medicine Advisory Bulletin 11.5: Rule Review & Roadmap

From the Eleusinian Mysteries to Modern Mysticism: The Role of Religion...

Analysis: FDA Advisory Committee Snubs MDMA-Assisted Therapy for PTSD in Overwhelming...

EDITOR PICKS

At the Federal Psychedelic Medicine Summit, the Mood Was Urgent, Practical,...

Bit Yaden on Preparing the Next Generation of Psychiatrists for a...

“If I can’t change my views based on evidence, then why...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.